Biocon Share Price
(BIOCON)
Check the latest share price of Biocon, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
as on 04:01PM, 12 May 2025
NSE
Biocon Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹317.9Day's Price Range₹336.352 Week's Low
52 Week's High
₹269.5552-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | + 0.32 % |
| 3 Month Return | -7.32 % |
| 1 Year Return | + 9.37 % |
| 3 Year Return | + 0.59 % |
| 5 Year Return | -3.95 % |
| Market Stats | |
| Previous Close | ₹329.90 |
| Open | ₹335.00 |
| Volume | 75.78L |
| Upper Circuit | ₹362.85 |
| Lower Circuit | ₹296.95 |
Biocon Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹39,607.79 Cr
Return on Equity (ROE)
0.97
PE Ratio (TTM)
38.95
Return on capital employed (ROCE)
2.61
Industry PE ratio
53.76
Beta (LTM)
1.27
P/B Ratio
2.91
Dividend Yield
0.19
PEG Ratio
-486.87
Quarterly Earnings Growth YOY
106.1
EPS (TTM)
10.81
Sector
Pharmaceuticals
Book Value
164.77
Technical Analysis
Bearish
View Technical Analysis
How to invest in Biocon
Investing in Biocon is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Biocon or BIOCON on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Biocon or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Biocon with just a few clicks!
Biocon Stock's Interest Amongst Investors
Biocon Valuation
Track how the P/E of Biocon has moved over time to understand valuation trends.
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (38.95x)
May 9, 2025
Industry (53.76x)
May 9, 2025
Highest (118.86x)
September 27, 2018
Today’s Price to Earnings Ratio: 38.95x
Analysts Recommendation on Biocon
Get updated buy, sell, and hold recommendations by analysts on Biocon.
based on 20 analysts
57.89%
Buy
15.79%
Hold
26.32%
Sell
57.89% of analysts recommend a 'BUY' rating for Biocon. Average target price of ₹378.2
Source: S&P Global Market Intelligence
Analysts Forecast on Biocon
Get share price movements and forecasts by analysts on Biocon.
Biocon price forecast by 20 analysts
Upside of14.64%
High
₹452
Target
₹378.20
Low
₹260
Biocon target price ₹378.2, a slight upside of 14.64% compared to current price of ₹328.15. According to 20 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:39.62%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:50.35%
Forecast
Actual
Source: S&P Global Market Intelligence
Biocon Financials
Get the annual and quarterly financial summary of Biocon, including revenue, profit, loss and more.
Biocon Index Inclusions
Biocon Earnings and Dividends
View detailed summary of the earnings and dividend history of Biocon.
Biocon Ltd Earnings Results
Biocon Ltd’s net profit jumped 154.24% since last year same period to ₹344.50Cr in the Q4 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 1272.51% jump in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.61%.
Read More about Dividends
Biocon Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Biocon.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.66% | 0.00 | |
| Mutual Funds | 8.77% | 0.00 | |
| Retail Investors | 17.76% | 0.00 | |
| Others | 7.17% | 0.00 |
Biocon vs Peers
Compare market cap, revenue, PE, and other key metrics of Biocon with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 39,607.79 | -0.79% | 0.58 | 1,297 | 14,755 | |
| HOLD | 1,59,958.09 | 30.99% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,06,307.71 | 31.38% | 0.67 | 1,656 | 10,727 | |
| HOLD | 23,494.27 | -4.33% | 0.50 | 772 | 5,664 | |
| BUY | 1,19,530.78 | 31.92% | 0.50 | 4,155 | 25,774 |
Biocon News & Key Events
Latest news and events at one place to help you take investing decisions in Biocon.
Biocon Explores Merger with Biosimilars Arm - 12 May, 2025
Biocon Group's board is exploring strategic restructuring options, including a merger of Biocon Biologics with Biocon Ltd, while also planning to raise ₹4,500 crore.Biocon Optimistic About US Market Access - 11 May, 2025
Biocon is optimistic about its US market share, boasting over 70% payer access and covering 100 million lives. The company reported a 15% revenue increase in Q4 FY25, with significant growth in generics and biosimilars. Plans to raise ₹4,500 crore and explore restructuring options were also announced.Biocon Plans $150 Million Capex Investment - 10 May, 2025
Biocon intends to invest $150 million in capital expenditure, focusing on biologics and generics. The company reported a 153% surge in Q4 net profit, driven by strong product launches and a robust biosimilar pipeline.Biocon Reports Strong Q4FY25 Results - 08 May, 2025
Biocon Ltd announced impressive Q4FY25 results, with a 153% increase in net profit to ₹344 crore and a 12% rise in revenue to ₹4,454 crore. The company also plans to raise up to ₹4,500 crore for strategic investments. The generics business saw a 46% revenue increase, and Syngene achieved over ₹1,000 crore in quarterly revenue for the first time.Axis Securities Issues Buy Call on Biocon - 07 May, 2025
Axis Securities has given a Buy recommendation for Biocon with a target price of Rs 351, citing strong product pipeline and market growth. The company reported a consolidated total income of Rs 3,856.20 crore for the latest quarter, showing a 6.44% increase from the previous quarter. Promoters hold a significant stake, indicating confidence in the company's future.Biocon Secures Major Market Access for Yesintek - 05 May, 2025
Biocon Biologics has obtained significant market access agreements for its biosimilar Yesintek, approved for chronic autoimmune diseases, covering over 100 million lives in the U.S. This milestone reflects strong adoption by payors, enhancing Biocon's market position.Biocon Shares Surge on Positive EU Biosimilar Review - 28 Apr, 2025
Biocon Ltd's shares increased by 3.3% following positive recommendations from the European Medicines Agency for its denosumab biosimilars. This development enhances Biocon's global market presence and boosts investor confidence.Biocon Plans Major Fundraising for Growth - 24 Apr, 2025
Biocon's board has approved raising up to ₹4,500 crore through various methods to support future growth plans. The company also reported a significant decline in net profit for Q3 FY25.Biocon Plans Major Fundraising Initiative - 23 Apr, 2025
Biocon Limited's board has approved a plan to raise up to ₹4,500 crore through various securities, including equity and debt instruments, to strengthen its financial position and support growth initiatives.Biocon Board Meeting to Discuss Fundraising Proposal - 20 Apr, 2025
Biocon Limited's board meeting on April 23, 2025, will consider a fundraising proposal to strengthen its balance sheet and support growth initiatives. The company may raise funds through various methods, pending approvals.Biocon Secures U.S. Launch for Yesafili Biosimilar - 15 Apr, 2025
Biocon Biologics has reached a settlement with Regeneron to commercialize Yesafili, an interchangeable biosimilar to Eylea, in the U.S. by 2026. This agreement enhances Biocon's presence in ophthalmology and includes a similar launch in Canada by July 2025.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 8.58% to 8.77% in Mar 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 3.64K Cr → 4.47K Cr (in ₹), with an average increase of 9.6% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -16.0 Cr → 344.5 Cr (in ₹), with an average increase of 128.2% per quarter
NO EFFECTFII Holding Unchanged
Foreign Institutions holdings remained unchanged at 5.66% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Vimta Labs Ltd has given 180.6% return, outperforming this stock by 180.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 95.2% return, outperforming this stock by 85.8%
NEGATIVE IMPACTPrice Dip
In the last 6 months, BIOCON stock has moved down by -5.1%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 18.12% to 17.76% in Mar 2025 quarter
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Revenue: ₹4,358.10Cr as on March 2025 (Q1 25)
Net Profit: ₹459.40Cr as on March 2025 (Q1 25)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon Ltd |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| CEO | Kiran Mazumdar Shaw |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Biocon
Check out the Mutual Funds with significant holdings in Biocon.
FAQs
What is Biocon Ltd price today?
Biocon Ltd share price today stands at ₹328.15, Open: ₹335, Previous Close: ₹329.9, High: ₹336.3, Low: ₹317.9, 52 Week High: ₹404.7, 52 Week Low: ₹269.55.
How to Buy Biocon Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Biocon Ltd shares
What are today's traded volumes of Biocon Ltd?
Today's traded volume of Biocon Ltd(BIOCON) is 75.78L.
What is today's market capitalisation of Biocon Ltd?
Today's market capitalisation of Biocon Ltd(BIOCON) is ₹39,607.79 Cr.
What is the 52 Week High and Low Range of Biocon Ltd?
How much percentage Biocon Ltd is down from its 52 Week High?
Biocon Ltd (BIOCON) share price is ₹328.15. It is down -18.92% from its 52 Week High price of ₹404.7
How much percentage Biocon Ltd is up from its 52 Week low?
Biocon Ltd (BIOCON) share price is ₹328.15. It is up 21.74% from its 52 Week Low price of ₹269.55